Genfit S.A. (OTCMKTS:GNFTF) Short Interest Update

Genfit S.A. (OTCMKTS:GNFTF) saw a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 76,400 shares, an increase of 6.1% from the June 30th total of 72,000 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is currently 764.0 days.

Genfit Price Performance

OTCMKTS GNFTF opened at $5.53 on Friday. Genfit has a one year low of $2.95 and a one year high of $5.53. The company has a 50-day simple moving average of $5.28 and a 200-day simple moving average of $3.89.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.